Order results by:
| Issue | Title | |
| Vol 16, No 5 (2020) | New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev | ||
| "... candidate genes. Results. Among the patients with bleeding who received dabigatran, 13 variants ..." | ||
| Vol 17, No 1 (2021) | Pharmacokinetics and Pharmacogenetics of Dabigatran | Abstract similar documents |
| A. V. Savinova, V. S. Dobrodeeva, M. M. Petrova, R. F. Nasyrova, N. A. Shnayder | ||
| "... Dabigatran etexilate is a prodrug of dabigatran, a oral direct inhibitor of thrombin ..." | ||
| Vol 13, No 3 (2017) | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION | Abstract similar documents |
| A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko | ||
| "... on dabigatran pharmacokinetics. It is known the case of gastrointestinal bleeding in the carrier of allelic ..." | ||
| Vol 16, No 5 (2020) | The CES1 Gene rs2244613 Minor Allele Impact on the Safety Profile of Dabigatran Etexilate: Meta-Analysis | Abstract similar documents |
| S. P. Abdullaev, K. B. Mirzaev, P. O. Bochkov, I. N. Sychev, D. A. Sychev | ||
| "... influence on the equilibrium concentration and the risk of bleeding during dabigatran taking. Material ..." | ||
| Vol 17, No 2 (2021) | Dynamics of Kidney Function in Patients with Chronic Kidney Disease and Atrial Fibrillation Who Receive Dabigatran | Abstract PDF (Eng) similar documents |
| N. A. Novikova, Z. K. Salpagarova, M. I. Chashkina, A. A. Bykova, Z. A. Alimova, А. S. Yadykina, D. F. Mesitskaya, N. A. Babakova, D. A. Andreev | ||
| "... of the anticoagulant therapy in the outpatient practice. Initially, 133 dabigatran taking patients were enrolled ..." | ||
| Vol 9, No 5 (2013) | PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| E. D. Kosmacheva, S. G. Kanorskiy, A. A. Kastanayan, N. V. Haylo, D. B. Goltyapin, E. A. Lipnitskaya, M. E. Statsenko | ||
| "... dabigatran etexilate, in the stroke prevention in patients with atrial fibrillation are considered. Factors ..." | ||
| Vol 12, No 4 (2016) | Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true | Abstract similar documents |
| Yu. A. Bunin, S. V. Miklishanskaya | ||
| Vol 18, No 5 (2022) | Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova | ||
| "... thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According ..." | ||
| Vol 10, No 4 (2014) | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..." | ||
| Vol 13, No 1 (2017) | DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT | Abstract similar documents |
| D. А. Napalkov, A. A. Sokolova, V. V. Fomin | ||
| "... anticoagulants, apixaban is associated with the best adherence to treatment and lowest bleeding incidence ..." | ||
| Vol 15, No 6 (2019) | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation | Abstract similar documents |
| M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... significant bleedings were recorded, 10 occurred in patients taking dabigatran and 9 in those taking ..." | ||
| Vol 15, No 5 (2019) | Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... . Awareness of side effects is mostly associated with bleeding risks while other problems with the use ..." | ||
| Vol 17, No 2 (2021) | Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions | Abstract similar documents |
| V. A. Ionin, O. I. Bliznuk, E. I. Baranova, E. V. Shlyakhto | ||
| "... , the risk of stroke and systemic embolism, the risk of bleeding, the anticoagulant therapy (ACT) recommended ..." | ||
| Vol 8, No 6 (2012) | HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| S. V. Moiseev | ||
| "... Dabigatran is the new oral anticoagulant that directly inhibits thrombin (factor IIa). In RE-LY ..." | ||
| Vol 13, No 6 (2017) | PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS | Abstract similar documents |
| A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin | ||
| "... were observed between minor bleeding frequency in both groups (16.33% in dabigatran group and 22 ..." | ||
| Vol 9, No 6 (2013) | THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | Abstract similar documents |
| A. V. Shulkin, E. N. Yakusheva, N. M. Popova | ||
| "... , prasugrel) and anticoagulants (dabigatran etexilate, rivaroxaban, edoxaban) is not feasible in routine ..." | ||
| Vol 16, No 6 (2020) | An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? | Abstract similar documents |
| T. V. Pavlova | ||
| "... , the comorbidity increases the risk of bleeding. Older age is also the risk factor of thrombotic and hemorrhagic ..." | ||
| Vol 16, No 1 (2020) | The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation | Abstract similar documents |
| A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva | ||
| "... -VASс 4.81±0.4 points) and >1 risk factor for bleeding (HAS-BLED 3.01±0.2 points). The duration ..." | ||
| Vol 7, No 1 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS | Abstract similar documents |
| M. Yu. Gilyarov, V. A. Sulimov | ||
| "... are considered. Special attention are paid to the direct thrombin inhibitors — dabigatran. Possibilities ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova | ||
| Vol 19, No 3 (2023) | Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants | Abstract similar documents |
| S. R. Gilyarevsky, N. K. Vereina, M. V. Golshmid | ||
| "... , in the development of severe bleeding or the need for urgent surgical intervention. The advantages and limitations ..." | ||
| Vol 17, No 5 (2021) | Gastrointestinal Bleeding: a Cardiologist's Point of View | Abstract similar documents |
| O. V. Averkov, L. N. Mishchenko | ||
| "... antagonists (warfarin) as well as direct oral anticoagulants (DOAC): dabigatran, rivaroxaban, apixaban ..." | ||
| Vol 12, No 5 (2016) | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation | Abstract similar documents |
| N. A. Novikova, A. N. Volovchenko | ||
| "... events in patients with AF. Possibility to perform planned cardioversion while receiving dabigatran has ..." | ||
| Vol 12, No 5 (2016) | Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| I. S. Daabul, A. A. Sokolova, D. A. Napalkov | ||
| "... of major bleedings significantly increases that considerably complicates the choice of adequate ..." | ||
| Vol 13, No 5 (2017) | DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov | ||
| Vol 7, No 6 (2011) | DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER | Abstract similar documents |
| I. S. Yavelov | ||
| "... Application of dabigatran etexilate for prevention of cardioembolic complications in nonvalvular ..." | ||
| Vol 16, No 2 (2020) | The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... of cohort and observational studies in real clinical practice on the influence of dabigatran etexilate ..." | ||
| Vol 13, No 5 (2017) | Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells | Abstract similar documents |
| Sergey Nikolaevich Bel'diev, Irina Vladimirovna Medvedeva, Dmitry Jur'evich Platonov | ||
| Vol 16, No 5 (2020) | Pharmacokinetics and Pharmacogenetics of Apixaban | Abstract similar documents |
| A. V. Savinova, M. M. Petrova, N. A. Shnayder, E. N. Bochanova, R. F. Nasyrova | ||
| "... , ABCG2) in its efficacy and safety are not well understood, and ABCB1 and ABCG2 genes may be potential ..." | ||
| Vol 18, No 3 (2022) | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art | Abstract similar documents |
| S. R. Gilyarevsky | ||
| "... interactions of apixaban, rivaroxaban and dabigatran with the drugs most frequently used in patients ..." | ||
| Vol 12, No 2 (2016) | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE | Abstract similar documents |
| S. V. Moiseev | ||
| "... (dabigatran), today are increasingly replacing warfarin and other indirect anticoagulants in preventing stroke ..." | ||
| Vol 7, No 5 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES | Abstract similar documents |
| Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy | ||
| Vol 9, No 3 (2013) | ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT | Abstract similar documents |
| E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts | ||
| Vol 11, No 3 (2015) | ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran ..." | ||
| Vol 9, No 4 (2013) | COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE | Abstract similar documents |
| L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky | ||
| "... Aim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non ..." | ||
| Vol 9, No 4 (2013) | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS | Abstract similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova | ||
| Vol 16, No 1 (2020) | Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice | Abstract similar documents |
| A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko | ||
| Vol 17, No 1 (2021) | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction | Abstract similar documents |
| Z. D. Kobalava, A. A. Shavarov, M. V. Vatsik-Gorodetskaya | ||
| Vol 8, No 1 (2012) | PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov | ||
| "... According to recent guidelines, oral dabigatran etexilate is indicated for stroke and systemic ..." | ||
| Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... , rivaroxaban and dabigatran. Along with clinical efficacy and safety profile one of the main characteristics ..." | ||
| Vol 9, No 5 (2013) | APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA | Abstract similar documents |
| D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev | ||
| Vol 14, No 3 (2018) | THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE | Abstract similar documents |
| I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... , it was decided to replace apixaban with another direct oral anticoagulant – dabigatran 150 mg bid for a period ..." | ||
| Vol 14, No 4 (2018) | Hepatotoxicity of New Oral Anticoagulants | Abstract similar documents |
| A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin | ||
| Vol 20, No 4 (2024) | Should a physician use the Beers criteria when prescribing direct oral anticoagulants to elderly patients? | Abstract similar documents |
| N. M. Vorobyeva, I. P. Malaya, V. D. Zakiev, O. N. Tkacheva | ||
| Vol 20, No 1 (2024) | Effect of CYP3A4/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis | Abstract similar documents |
| l. V. Fedina, i. N. Sychev, K. V. Mirzaev, A. V. Vardanyan, S. V. Glagolev, A. A. Kachanova, P. O. Bochkov, R. V. Shevchenko, S. N. Tuchkova, I. V. Sychev, S. P. Abdullaev, D A. Sychev | ||
| "... not affect the pharmacokinetics of apixaban and the risk of bleeding. We also identified the effect of ABCB1 ..." | ||
| Vol 18, No 6 (2022) | Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants | Abstract similar documents |
| A. D. Aga, A. A. Sokolova, D. A. Napalkov | ||
| Vol 11, No 3 (2015) | PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT | Abstract similar documents |
| A. V. Rudakova | ||
| "... average prices of public bidding for the purchase of drugs (enoxaparin, dabigatran and apixaban) during ..." | ||
| Vol 17, No 4 (2021) | Effect of Direct Oral Anticoagulants for Ulcer Epithelization and Laser Doppler Flowmetry Parameters In Patients with Diabetic Foot Syndrome and Atrial Fibrillation | Abstract similar documents |
| V. I. Petrov, N. V. Rogova, T. N. Кuzmina, A. S. Lishuta | ||
| "... for DFS and rivaroxaban (group 1; n=24) or combination therapy for DFS and dabigatran (group 2; n=22 ..." | ||
| Vol 11, No 2 (2015) | ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY | Abstract PDF (Eng) similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova, A. V. Jilenko, O. S. Anikina | ||
| "... % of the patients received novel oral anticoagulants (dabigatran – 14%, rivaroxaban – 2%). Bleeding was fixed in 4 ..." | ||
| Vol 9, No 2 (2013) | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES | Abstract similar documents |
| Z. M. Safiullina, S. V. Shalaev | ||
| "... Studies data on new anticoagulants, direct oral thrombin inhibitor (dabigatran) and direct ..." | ||
| Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
| "... therapy turned out to be the most promising for clinical use, since studies with dabigatran and apixaban ..." | ||
| Vol 10, No 2 (2014) | SECONDARY PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: THE CLINICIANS’ VIEWPOINT | Abstract similar documents |
| E. A. Drozdova | ||
| "... assessment of warfarin and dabigatran therapies is given. ..." | ||
| Vol 13, No 5 (2017) | WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT | Abstract similar documents |
| S. Yu. Martsevich, Y. V. Lukina | ||
| "... of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..." | ||
| Vol 18, No 6 (2022) | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis | Abstract similar documents |
| L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev | ||
| "... Aim. To investigate the effect of ABCB1 gene carriage and interdrug interactions on apixaban ..." | ||
| Vol 15, No 6 (2019) | Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study) | Abstract similar documents |
| S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, S. N. Tolpygina, V. P. Voronina, N. A. Dmitrieva, O. V. Lerman, N. A. Komkova | ||
| "... recommended the use of rivaroxaban; 47 (23.4%) – the use of dabigatran and 43 (21.4%) – the use of apixaban ..." | ||
| Vol 16, No 6 (2020) | The Oral Anticoagulants Administration in Elderly Patients with Geriatric Syndromes: What's New? | Abstract similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... is presented. Most studies indicate significant advantages of direct oral anticoagulants (dabigatran ..." | ||
| Vol 14, No 6 (2018) | Specific Antidotes for Direct Oral Anticoagulants in Life-Threatening Bleeding | Abstract PDF (Eng) similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, N. V. Lomakin | ||
| "... anticoagulants (DOACs) inhibitors, as antidotes for DOAC when stopping life-threatening bleeding. DOAC therapy ..." | ||
| Vol 20, No 5 (2024) | Effectiveness and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis of clinical trials | Abstract similar documents |
| E. M. Mezhonov, Z. M. Safiullina, Y. A. Vyalkina, S. V. Shalaev | ||
| "... " or "dabigatran" or "apixaban" or "rivaroxaban" and "vitamin K antagonist" or "warfarin" and "outcomes". ROBINS-I ..." | ||
| Vol 6, No 4 (2010) | CLOPIDOGREL PHARMACOGENETICS | Abstract similar documents |
| A. N. Meshkov | ||
| Vol 18, No 1 (2022) | Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev, K. G. Pereverzeva, A. Yu. Timakova, A. S. Galus, S. S. Yakushin | ||
| "... .6%) and dabigatran (17.3%) and warfarin (19.4%) were prescribed almost twice as rarely as rivaroxaban ..." | ||
| Vol 12, No 4 (2016) | Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation | Abstract similar documents |
| S. G. Kanorskii | ||
| "... . Conclusions of major bleeding, symptomatic thromboembolic complications (stroke, systemic embolism, transient ..." | ||
| Vol 6, No 5 (2010) | THE INVASIVE DENTAL PROCEDURES IN PATIENTS TREATING WITH WARFARIN: POSSIBILITIES AND PROSPECTS FOR SAFETY | Abstract similar documents |
| T. V. Kozlova, I. M. Makeyeva, V. Y. Doroshina, S. I. Bokareva | ||
| "... ) for a long time and needed in dental treatment are discussed. Assessment of bleeding and thromboembolism risk ..." | ||
| Vol 8, No 4 (2012) | THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY | Abstract similar documents |
| M. Yu. Gilyarov | ||
| Vol 14, No 4 (2018) | Antithrombotic Therapy after Bleeding in Elderly Polimorbid Patient: Our Time Challenge | Abstract similar documents |
| M. R. Atabegashvili, M. Yu. Gilyarov, E. V. Konstantinova, A. N. Kostina, A. P. Nesterov, T. D. Pakharkova, A. E. Udovichenko | ||
| "... associated with bleeding from the upper sections of the gastrointestinal tract, and severe anemia ..." | ||
| Vol 14, No 4 (2018) | Risk Controlling of Gastrointestinal Bleeding in Comorbid Patients with Cardiovascular Diseases | Abstract similar documents |
| O. Yu. Chizhova, L. N. Belousova, I. G. Bakulin | ||
| "... hemorrhagic complications, especially gastrointestinal bleeding, remain unresolved. Currently ..." | ||
| Vol 14, No 5 (2018) | Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case | Abstract similar documents |
| M. A. Andreyanova, K. B. Mirzaev, D. A. Sychev, K. A. Ryzhikova, A. V. Pokrovsky, A. F. Kharazov | ||
| "... therapy in this patient, namely, the carriage of polymorphic markers of the ABCB1 CT, CES1 CA and CYP3 ..." | ||
| Vol 17, No 5 (2021) | Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy | Abstract PDF (Eng) similar documents |
| E. S. Mazur, V. V. Mazur, N. D. Bazhenov, Yu. A. Orlov | ||
| "... at the level of 2-3, 14 (20.6%) started or continued taking dabigatran at a dose of 150 mg 2 times/day, 14 (20 ..." | ||
| Vol 21, No 2 (2025) | Anticoagulant therapy in patients with cardioembolic subtype of ischemic stroke and atrial fibrillation | Abstract similar documents |
| E. A. Naryshkina, M. I. Chashkina, E. S. Zadykyan, N. K. Kurnabalieva, E. M. Zakaryan, M. V. Serova, D. A. Andreev, A. G. Komarova, K. E. Eroshkin, A. A. Kulesh, D. A. Sychev | ||
| "... on outpatient ACT were included; rivaroxaban (n=56), apixaban (n=30), dabigatran etexilate (n=11), and warfarin ..." | ||
| Vol 19, No 1 (2023) | Value of Safety of Anticoagulant Therapy in Elderly Patient with Atrial Fibrillation and High Risk of Bleeding | Abstract similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... with atrial fibrillation and high risk of bleeding. An evidence base is presented demonstrating the high ..." | ||
| Vol 17, No 1 (2021) | Using the ORACLE Risk Score to Assess Hemorrhagic Risk in Patients with Acute Coronary Syndrome and Atrial Fibrillation | Abstract PDF (Eng) similar documents |
| V. A. Brazhnik, L. O. Minushkina, A. D. Erlikh, E. D. Kosmacheva, M. A. Chichkova, N. R. Khasanov, D. A. Zateyshchikov | ||
| "... Aim. To study the prognostic value of the ORACLE risk score for assessing the risk of bleeding ..." | ||
| Vol 19, No 3 (2023) | Recurrent bleeding during standard anticoagulant therapy in comorbid patients with atrial fibrillation: a clinical case report | Abstract similar documents |
| A. A. Kudriavtseva, E. V. Kolpachkova, Z. A. Gebekova, T. A. Sadulaeva, A. A. Sokolova, D. A. Napalkov | ||
| Vol 19, No 5 (2023) | Non-immunogenic staphylokinase in the treatment of high-risk massive pulmonary embolism in the early postoperative period due to femoral fragment wound | Abstract similar documents |
| S. L. Konstantinov, G. I. Stryabkova, A. I. Basarab, V. N. Kravchuk, I. V. Kаzhanov, S. V. Ivanov, Zh. Yu. Chefranova, S. S. Markin | ||
| "... staphylokinase did not lead to the major bleeding and hemorrhagic stroke, did not provoke a drop in hemoglobin ..." | ||
| Vol 10, No 3 (2014) | COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. V. Rudakova, V. A. Parfenov | ||
| "... anticoagulants such as apixaban, rivaroxaban and dabigatran. Administration of vitamin K antagonists (VKA ..." | ||
| Vol 14, No 5 (2018) | Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, M. A. Gabitova, L. N. Uddin | ||
| "... with atrial fibrillation: those who have high bleeding and high thromboembolic risk and elderly. The focus ..." | ||
| Vol 21, No 1 (2025) | The Beers criteria role in predicting bleeding during the use of direct oral anticoagulants in patients with atrial fibrillation over 80 years of age | similar documents |
| M. S. Cherniaeva, M. A. Rozhkova, E. S. Ilyina, E. A. Moiseeva, E. A. Gorelov, L. A. Egorova, O. M. Maslennikova, N. V. Lomakin, D. A. Sychev | ||
| Vol 11, No 5 (2015) | New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation | Abstract similar documents |
| article Editorial | ||
| "... New data of the real clinical practice confirms low incidence of major bleeding when using ..." | ||
| Vol 18, No 5 (2022) | Thrombodynamics Test in Assessing the Risk of Thrombus Formation in Patients with Atrial Fibrillation Taking Direct Oral Anticoagulants | Abstract PDF (Eng) similar documents |
| Z. A. Gebekova, I. I. Ivanov, A. Asambayeva, A. I. Skripka, A. A. Sokolova, D. A. Napalkov, T. A. Vuimo | ||
| "... no history of thrombosis or bleeding before inclusion in this study. All parameters of Thrombodynamics test ..." | ||
| Vol 11, No 2 (2015) | PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST | Abstract similar documents |
| D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii | ||
| "... of patients with bleeding because of apixaban therapy (including antidotes application), perioperative ..." | ||
| Vol 15, No 1 (2019) | Assessment of Antithrombotic Therapy in Patients with Atrial Fibrillation for 2015-2017 According to the Registry of the Clinic of the Scientific Research Institute of Medical Problems of the North of Krasnoyarsk City | Abstract similar documents |
| A. A. Tuchkov, N. G. Gogolashvili, R. A. Yaskevich | ||
| "... of bleeding on the HAS-BLED scale. The incidence of ATT at the prehospital stage was assessed depending ..." | ||
| Vol 21, No 1 (2025) | Practical aspects of perioperative management in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants | Abstract similar documents |
| E. N. Markova, T. Yu. Vedenikin, A. A. Kuzub, N. V. Kuchieva, A. R. Navasardyan, O. N. Dzhioeva | ||
| "... anticoagulant therapy, including the classification of surgical procedures by bleeding risk, type of anesthesia ..." | ||
| Vol 19, No 5 (2023) | Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease | Abstract similar documents |
| N. A. Shatalova, D. A. Sychev, K. B. Mirzaev, A. I. Kochetkov, E. Yu. Ebzeeva, V. B. Dashabylova, P. O. Bochkov, S. N. Tuchkova, S. V. Glagolev | ||
| "... Aim. To study the possible relationship between polymorphic variants of ABCB1 (rs2032582, rs ..." | ||
| Vol 14, No 4 (2018) | Possibilities of Using Rivaroxaban in Elderly Patients with Atrial Fibrillation: Data from Randomized Studies and Real Clinical Practice | Abstract similar documents |
| N. M. Vorobyeva, O. N. kacheva | ||
| "... stroke by 41% with a comparable risk of major bleeding in patients older than 80 years. In another study ..." | ||
| Vol 12, No 1 (2016) | Acute coronary syndrome and renal dysfunction | Abstract similar documents |
| F. I. Belyalov | ||
| "... the risk of bleeding. It is important to aim for treatment based on the evidence-based studies ..." | ||
| Vol 16, No 2 (2020) | The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment | Abstract similar documents |
| К. V. Lobastov, I. V. Schastlivtsev | ||
| "... ) is associated with an increased risk of VTE recurrence and bleeding, so low molecular weight heparin (LMWH ..." | ||
| Vol 14, No 3 (2018) | APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova | ||
| "... on the risks of ischemic events associated with stenting, the risk of ischemic stroke and bleeding. Use of new ..." | ||
| Vol 15, No 3 (2019) | Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population | Abstract similar documents |
| K. B. Mirzaev, D. S. Fedorinov, D. V. Ivashchenko, D. A. Sychev | ||
| "... », «CYP4F2», «CYP4F1», «ABCB1», «SLCO1B1», «VKORC1», «GGCX», «SULT1A1», «CULT1», «CES1», «gene», «genes ..." | ||
| Vol 18, No 6 (2022) | Perioperative Management of Patients Receiving Antithrombotic Therapy in Schemes and Algorithms | Abstract similar documents |
| O. N. Dzhioeva, E. A. Rogozhkina, O. M. Drapkina | ||
| "... , as it increases the risk of bleeding. In this regard, a fundamentally important and complex question arises: how ..." | ||
| Vol 12, No 5 (2016) | The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin | Abstract similar documents |
| I. Yu. Koroleva, I. V. Kolesnichenko, V. P. Nosov, M. V. Zlobin, D. I. Abelevich | ||
| "... stroke and systemic thromboembolic complications (TEC), bleeding in patients with non-valvular atrial ..." | ||
| Vol 13, No 4 (2017) | COMPARATIVE RESULTS OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE AND TENECTEPLASE USE IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN REAL CLINICAL PRACTICE | Abstract similar documents |
| E. S. Mazur, R. M. Rabinovich, V. V. Mazur, N. S. Kuznetsova, E. A. Kudryashova, S. V. Veselov, V. V. Bobkov, D. Yu. Platonov | ||
| "... reperfusion criteria were evaluated as well as clinical outcomes – mortality, reinfarction, stroke, bleeding ..." | ||
| Vol 14, No 2 (2018) | NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING | Abstract similar documents |
| Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov | ||
| "... of intracranial bleeding. There was significant increasing number of publications addressed to use of DOACs ..." | ||
| Vol 14, No 5 (2018) | Excessive Hypocoagulation in Therapy with Warfarin within Polypharmacy: Using online database Multi-Drug Interaction Checker and Graphic “Time-Effect-Drug Administration” to Eliminate Adverse Drug Event (Case Report) | Abstract similar documents |
| G. S. Krasnov, I. V. Kazancev | ||
| "... fibrillation and comorbidity. The patient had excessive polypharmacy level (11 drugs). Minor bleeding developed ..." | ||
| Vol 12, No 2 (2016) | THE RESULTS OF USE OF NEW NATIVE THROMBOLYTIC IN CLINICAL PRACTICE | Abstract similar documents |
| E. S. Mazur, R. M. Rabinovich, V. V. Mazur, N. S. Kuznetsova, E. A. Kudryashova, S. V. Veselov | ||
| "... . Bleedings, anaphylaxis and total mortality were considered. Results. The ST-segment resolution up to 70 ..." | ||
| Vol 13, No 1 (2017) | ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY | Abstract similar documents |
| E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko | ||
| "... candidates for anticoagulant therapy for reasons other than bleeding risk or those who refuse to take oral ..." | ||
| Vol 12, No 1 (2016) | Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita | Abstract similar documents |
| S. N. Bel'diev | ||
| "... in plasma concentrations of rivaroxaban that is accompanied by increased risk of bleeding. According ..." | ||
| Vol 7, No 1 (2011) | NEW ANTIPLATELET DRUGS (PART 1) | Abstract similar documents |
| A. B. Sumarokov | ||
| "... of excessive action leading to the bleeding. Possibility to control pharmacodynamics effects of antiplatelet ..." | ||
| Vol 7, No 5 (2011) | NEW ANTIPLATELET DRUGS. PART 2 | Abstract similar documents |
| A. B. Sumarokov | ||
| "... of excessive action, leads to the bleeding. The ability to monitor antiplatelet pharmacodynamics is still very ..." | ||
| Vol 16, No 5 (2020) | Doctors’ Adherence to the Guidelines on the Oral Anticoagulants Usage | Abstract similar documents |
| N. B. Perepech, I. E. Mikhailova, A. V. Tregubov | ||
| "... possible bleeding. Overestimation of the bleeding risk is more often among therapists than cardiologists ..." | ||
| Vol 7, No 4 (2011) | EFFICACY AND SAFETY OF GLYCOPROTEIN IIB/IIIA BLOCKER MONOFRAM IN CORONARY STENTING IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION | Abstract similar documents |
| E. I. Makhiyanova, A. S. Galyavich | ||
| "... patients. Deaths, stent thrombosis, individual intolerance, allergic reactions, bleeding were registered ..." | ||
| Vol 19, No 6 (2023) | Platelet phenotypes and practical aspects of platelet function testing in cardiology | Abstract similar documents |
| Zh. D. Kobalava, A. S. Pisaryuk, A. A. Filkova, E. S. Tukhsanboev, A. A. Boldyreva, D. P. Lazutova, I. A. Meray, M. A. Panteleev | ||
| "... as to predict the risk of intraoperative bleeding in these groups of patients. Later, laboratory platelet ..." | ||
| 1 - 100 of 143 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
